ASX Penny Stocks: Deep Yellow And 2 Other Promising Picks
ASX Growth Stocks With High Insider Confidence
Mesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline
Mesoblast's Ryoncil® generates $36M in net revenues for the quarter and $115M in the first year of launch.
Mesoblast posts Q4 Ryoncil net revenue of US$36 million
Australian Stocks Trading Below Fair Value Based On Cash Flows